Oxbow Advisors LLC Has $947,000 Position in Eli Lilly and Company (NYSE:LLY)

Oxbow Advisors LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 2.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,046 shares of the company’s stock after purchasing an additional 25 shares during the period. Oxbow Advisors LLC’s holdings in Eli Lilly and Company were worth $947,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Tidemark LLC bought a new position in Eli Lilly and Company during the fourth quarter worth about $29,000. Core Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $32,000. LGT Financial Advisors LLC bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $37,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $10.04 during midday trading on Friday, reaching $902.71. 3,439,999 shares of the company’s stock were exchanged, compared to its average volume of 3,063,074. The stock’s 50-day simple moving average is $895.97 and its 200 day simple moving average is $827.49. The firm has a market cap of $857.94 billion, a price-to-earnings ratio of 132.95, a P/E/G ratio of 2.91 and a beta of 0.41. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, analysts expect that Eli Lilly and Company will post 16.51 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 75,510 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $860.78, for a total value of $64,997,497.80. Following the completion of the sale, the insider now directly owns 97,793,810 shares in the company, valued at approximately $84,178,955,771.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 737,410 shares of company stock worth $669,719,100. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LLY shares. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Guggenheim increased their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America boosted their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. BMO Capital Markets increased their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Argus lifted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $961.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.